Navigation Links
Technology deal for next generation production of 'green whistle'
Date:7/9/2012

Australian healthcare company Medical Developments International (MDI) and CSIRO have signed a technology deal to develop a new production process for the drug methoxyflurane the pain-relieving ingredient used in Penthrox (commonly known as the green whistle).

If successful, the project will help MDI significantly reduce the cost of producing Penthrox and facilitate large-scale production to support the company's plan to sell Penthrox in the UK and Europe.

CSIRO is investing $750 000 under its Australian Growth Partnerships (AGP) program into the project which will strengthen MDI's position as the only global manufacturer of methoxyflurane.

MDI is seeking regulatory approval to sell the drug in the United Kingdom and Europe, which if granted, will see MDI increase production of the drug using CSIRO's manufacturing process.

Penthrox is used in Australia as an analgesic by emergency medical practitioners, the defence forces, ambulance and surf lifesaving services. Recently its applications have expanded into dentistry, general practitioners, cosmetics and other medical specialities such as endoscopy.

Penthrox has significant advantages over other analgesics such as nitrous oxide and morphine in that it is fast acting, self-administered, non-addictive, non-narcotic and safe to use and provides strong pain relief.

John Sharman, CEO of MDI, said: "The green whistle is already an iconic Australian product which we believe will offer an effective alternative to established products used in hospitals and emergency services in the UK, Europe and other parts of the world. Through our partnership with CSIRO, we hope to scale-up the production of methoxyflurane by developing a smarter, more efficient manufacturing process and in so doing assist MDI deliver on its promising future."

Paul Savage, CSIRO biotechnology program leader said: "Our AGP program is an excellent example of how innovative SMEs can access CSIRO's world-class research and development capability. This partnership demonstrates how forward-thinking Australian companies can benefit from R&D to grow locally and to expand into global markets."

Penthrox is made in Melbourne and sold in 11 countries around the world with regulatory applications pending approval in another 15 countries.

Australian companies CSIRO has invested in via its AGP program include Biofiba, Clover Corporation and Avipep.


'/>"/>
Contact: Simon Hunter
simon.hunter@csiro.au
61-395-458-412
CSIRO Australia
Source:Eurekalert

Related biology news :

1. Advanced Membrane Technology V Conference
2. University of North Texas Health Science Center Advances Forensic Research by Investing in Semiconductor DNA Sequencing Technology
3. Next-generation sequencing technology opens doors to discoveries
4. Weizmann Institute solar technology to convert greenhouse gas into fuel
5. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
6. Nanotechnology breakthrough could dramatically improve medical tests
7. NIH-funded study examines use of mobile technology to improve diet and physical activity behavior
8. New study shows how nanotechnology can help detect disease earlier
9. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
10. Purdue professor to speak before Congress about nanotechnology in brain treatment research
11. AAPS National Biotechnology Conference to highlight innovative vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network (HTVN) ... their fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited ... competition showcasing early stage digital health and med tech companies. , This day-long ...
(Date:10/5/2017)... , ... October 05, 2017 , ... LabRoots , ... scientists from around the world, is giving back to cancer research with a month-long ... , Now through October 31, shoppers can use promo code PinkRibbon to get ...
(Date:10/5/2017)... ... October 05, 2017 , ... ... new applications of its Nanobind DNA/RNA extraction technology . Nanobind is a ... on the surface and that can be used for a wide variety of ...
Breaking Biology Technology: